You are here : Home > Lisbon 2019 – February 25-27 > Program

Program

banner_lissabon

10th Open Scientific EIP Symposium
on
Immunogenicity of Biopharmaceuticals

 

1st Announcement

25 – 27 February 2019

Altis Hotel

Lisbon, Portugal

CONFIRMED SPEAKERS

TRAINING COURSE

Practical guidance for constructing an immunogenicity risk assessment

FDA representative
Paul Chamberlain, NDA Advisory Board

 

Major Challenges in the Assessment of Immunogenicity

EIP team

 

MAIN CONFERENCE

Keynote Lecture: Gene therapy

Federico Mingozzi, Spark Therapeutics

 

Tolerance induction to factor VIII

David W. Scott, USUHS

 

Impact of Aggregates and PTM on immunogenicity

Wim Jiskoot, UCLN

 

Immunogenicity testing

Boris Gorovits, Pfizer

 

Biosimilars

Martin Ullmann, Fresenius Kabi

 

Clinical relevance

Theo Rispens, Sanquin
Arno Kromminga, BioAgilytix

 

Non-clinical immunogenicity risk assessment

Nicolas Legrand, Axenis

 

Regulatory – Risk assessment of novel modalities/CAR-T/gene therapy constructs

Paul Chamberlain
FDA and EMA representatives

 

Novel predictive markers

P. Broet , Inserm